Valuation: Affimed N.V.

Market Cap 18.84M 21.04M 17.38M 15.73M 29.41M 2B 29.89M 207M 82.73M 1.05B 78.94M 77.26M 3.32B P/E 2022
-1.92x
P/E 2023 -0.8x
Enterprise Value -336K -375K -310K -281K -525K -35.75M -533K -3.7M -1.48M -18.71M -1.41M -1.38M -59.27M EV / Sales 2022
0.03x
EV / Sales 2023 4.69x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
1 day+200.00%
1 week+2,900.00%
Current month+2,900.00%
1 month+2,900.00%
3 months+2,900.00%
6 months+2,900.00%
Current year+2,900.00%
1 week 0
Extreme 0.0001
0
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 1.0E-6
0.04
1 year 0
Extreme 1.0E-6
0.05
3 years 0
Extreme 1.0E-6
8.95
5 years 0
Extreme 1.0E-6
73.5
10 years 0
Extreme 1.0E-6
117.4
Manager TitleAgeSince
Chief Executive Officer 42 2024-09-02
Director of Finance/CFO 61 2023-12-30
Chief Executive Officer 65 2024-01-14
Director TitleAgeSince
Chairman 75 2006-12-31
Director/Board Member 71 2016-01-20
Director/Board Member 60 2020-08-03
Change 5-day change 1-year change 3-year change Capi.($)
+200.00%+2,900.00%-49.15%-99.91% 16.39K
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-1.28%-1.57%+25.77%+54.64% 45.99B
-0.47%-2.90%+17.89%+98.91% 42.45B
+0.73%+1.23%+227.47%+935.42% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average +19.67%+93.44%+42.22%+136.95% 39.25B
Weighted average by Cap. -0.10%+3.13%+49.44%+160.91%

Financials

2022 2023
Net sales 42.87M 47.86M 39.55M 35.79M 66.92M 4.56B 68.01M 472M 188M 2.39B 180M 176M 7.55B 13.91M 15.53M 12.84M 11.62M 21.72M 1.48B 22.07M 153M 61.1M 774M 58.3M 57.06M 2.45B
Net income -86M -96.02M -79.34M -71.8M -134M -9.14B -136M -947M -378M -4.79B -360M -353M -15.16B -106M -118M -97.73M -88.44M -165M -11.26B -168M -1.17B -465M -5.89B -444M -434M -18.67B
Net Debt -172M -192M -159M -144M -269M -18.3B -273M -1.89B -756M -9.58B -721M -706M -30.33B -19.18M -21.41M -17.69M -16.01M -29.94M -2.04B -30.42M -211M -84.21M -1.07B -80.35M -78.64M -3.38B
Projected Income Statement - Annual - Affimed N.V.
Logo Affimed N.V.
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.
Employees
76
Date Price Change Volume
26-10-29 US$0.003000 +200.00% 20,255
26-10-27 US$0.001000 +900.00% 100,110
26-10-26 US$0.000100 0.00% 150
26-10-23 US$0.000100 0.00% 135
26-10-22 US$0.000100 0.00% 162,002

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Affimed N.V.
  1. Stock Market
  2. Stocks
  3. AFMDQ Stock